Name | idx 184 |
---|---|
Synonyms |
5’-O-[(benzylamino)[2-(3-hydroxy-2,2-dimethylpropionylsulfanyl)ethoxy]phosphoryl]-2’-C-methylguanosine
2’-C-methylguanosine-5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl-N-(phenylmethyl)phosphoramidate] IDX184 2'-C-methylguanosine-5'-[2-[(3-hydroxy-2,2-dimethyl-1-oxopropyl)thio]ethyl-N-benzylphosphoramidate] |
Description | IDX184 is a potent and orally bioavailable inhibitor of HCV replication. IDX184 potently inhibits HCV polymerase (IC50=0.31 μM, Ki=52.3 nM)[1][2]. |
---|---|
Related Catalog | |
Target |
IC50: 0.31 μM (HCV polymerase)[2] Ki: 52.3 nM (HCV polymerase)[2] |
In Vitro | IDX184 is a liver-targeted prodrug of the nucleotide 2′-MeG-MP. IDX184 is a liver-targeted nucleotide polymerase inhibitor of hepatitis C virus[1]. IDX184 is a second generation, orally bioavailable nucleotide prodrug designed to provide increased anti-HCV efficacy and safety versus the parent nucleoside. In HCV replicon testing, IDX184 is the most potent inhibitor (EC50=0.3-0.45 μM) compared to any of the 2’ or 4’ modified nucleosides (EC50=4-6 μM) and is also highly inhibitory in the JFH-1 infectious system (EC50=0.06-0.11 μM). IDX184 is not toxic (CC50>100μM) in any tested cell line[2]. |
References |
Molecular Formula | C25H35N6O9PS |
---|---|
Molecular Weight | 626.61900 |
Exact Mass | 626.19200 |
PSA | 259.25000 |
LogP | 1.89260 |